[HTML][HTML] Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german …
CP Schneider, D Heigener, K Schott-von-Römer… - Journal of Thoracic …, 2008 - Elsevier
Introduction Relationships between clinical outcomes and epidermal growth factor receptor
(EGFR)-related tumor markers were investigated in patients with advanced non-small cell …
(EGFR)-related tumor markers were investigated in patients with advanced non-small cell …
Phase II clinical trial of chemotherapy-naive patients≥ 70 years of age treated with erlotinib for advanced non–small-cell lung cancer
DM Jackman, BY Yeap, NI Lindeman… - Journal of Clinical …, 2007 - ascopubs.org
Purpose This is a phase II, multicenter, open-label study of chemotherapy-naïve patients
with non–small-cell lung cancer (NSCLC) and age≥ 70 years who were treated with …
with non–small-cell lung cancer (NSCLC) and age≥ 70 years who were treated with …
[HTML][HTML] A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non–small …
FR Hirsch, F Kabbinavar, T Eisen… - Journal of clinical …, 2011 - ncbi.nlm.nih.gov
Purpose Erlotinib prolongs survival in patients with advanced non–small-cell lung cancer
(NSCLC). We report the results of a randomized, phase II study of erlotinib alone or …
(NSCLC). We report the results of a randomized, phase II study of erlotinib alone or …
[PDF][PDF] Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR. 21
P Wheatley-Price, K Ding, L Seymour… - Journal of Clinical …, 2008 - researchgate.net
Purpose National Cancer Institute of Canada Clinical Trials Group Study BR. 21 established
erlotinib as a standard of care in patients with non–small-cell lung cancer (NSCLC) after …
erlotinib as a standard of care in patients with non–small-cell lung cancer (NSCLC) after …
TRIBUTE-A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC)
RS Herbst, D Prager, R Hermann, V Miller… - Journal of Clinical …, 2004 - ascopubs.org
7011 Background: Tarceva™(erlotinib) is a potent reversible HER1/EGFR tyrosine kinase
inhibitor with single-agent antitumor activity. TRIBUTE was a prospective, placebo-controlled …
inhibitor with single-agent antitumor activity. TRIBUTE was a prospective, placebo-controlled …
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre …
L Zhang, S Ma, X Song, B Han, Y Cheng… - The lancet …, 2012 - thelancet.com
Background Maintenance treatment of patients with advanced non-small-cell lung cancer
(NSCLC) without disease progression after first-line chemotherapy is a subject of ongoing …
(NSCLC) without disease progression after first-line chemotherapy is a subject of ongoing …
[PDF][PDF] Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non–small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
U Gatzemeier, A Pluzanska, A Szczesna… - Journal of Clinical …, 2007 - researchgate.net
Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …
[PDF][PDF] Randomized phase III trial of erlotinib versus docetaxel as second-or third-line therapy in patients with advanced non–small-cell lung cancer: Docetaxel and …
T Kawaguchi, M Ando, K Asami, Y Okano… - Journal of clinical …, 2014 - researchgate.net
Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in
Patients With Advanced Non–Small- Page 1 Randomized Phase III Trial of Erlotinib Versus …
Patients With Advanced Non–Small- Page 1 Randomized Phase III Trial of Erlotinib Versus …